[
    [
        {
            "time": "",
            "original_text": "药明康德(02359.HK)：胡正国辞任首席财务官，继续担任董事及联席首席执行官等职 董监高成员变化",
            "features": {
                "keywords": [
                    "药明康德",
                    "胡正国",
                    "首席财务官",
                    "董监高成员变化"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药明康德(02359.HK)：胡正国辞任首席财务官，继续担任董事及联席首席执行官等职 董监高成员变化",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "上交所：药明康德将被调入沪港通下港股通股票名单",
            "features": {
                "keywords": [
                    "上交所",
                    "药明康德",
                    "沪港通",
                    "港股通"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上交所：药明康德将被调入沪港通下港股通股票名单",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业: 国家集采文件落地, 顶层制度建设出台",
            "features": {
                "keywords": [
                    "医药生物",
                    "国家集采",
                    "顶层制度建设"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业: 国家集采文件落地, 顶层制度建设出台",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德(2359.HK)：春华秋实，一丛金黄，首次给予“买入”评级，目标价101.9港元",
            "features": {
                "keywords": [
                    "药明康德",
                    "买入评级",
                    "目标价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(2359.HK)：春华秋实，一丛金黄，首次给予“买入”评级，目标价101.9港元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本张磊：做深研究才能为风险定价",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "张磊",
                    "风险定价"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "高瓴资本张磊：做深研究才能为风险定价",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "生物医药行业: 国家版带量采购方案出台, 推进速度预计加快",
            "features": {
                "keywords": [
                    "生物医药",
                    "国家版",
                    "带量采购",
                    "推进速度"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "生物医药行业: 国家版带量采购方案出台, 推进速度预计加快",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]